Mergers & Acquisitions ·
Chemomab Therapeutics reported a net loss of $3.9 million for the six months ended June 30, 2026, with cash and…
CMMBChemomab Therapeutics Ltd.
Chemomab Therapeutics reported a net loss of $3.9 million for the six months ended June 30, 2026, with cash and short-term deposits totaling $6.7 million. The company disclosed a subsequent event on July 7, 2026: a definitive merger agreement with Scipher Medicine Corporation to form a combined U.S.-based entity trading as SCIP on Nasdaq. Under the all-stock transaction, Chemomab shareholders will own approximately 32% of the combined company, while Scipher shareholders will hold 68%. The deal includes a concurrent private placement (PIPE) for at least $30 million and contingent value rights for Chemomab holders tied to nebokitug milestones. The combined entity plans to advance nebokitug into a Phase 2 precision medicine trial in rheumatoid arthritis, leveraging Scipher’s diagnostic platform. Chemomab Therapeutics operates as a clinical-stage biotechnology company focused on discovering and developing therapeutics for inflammatory and fibrotic conditions.